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TObjectives: The Cox maze procedure is the gold standard for ablation of atrial
fibrillation in patients undergoing mitral valve surgery, and new approaches to atrial
fibrillation ablation must be compared with it. Therefore, we sought to determine the
time-related prevalence of atrial fibrillation and its risk factors after combined Cox
maze and mitral valve surgery.
Methods: From November 1991 through January 2004, 263 patients (mean left atrial
diameter, 5.8  1.2 cm) underwent combined mitral valve surgery (repair in 71%)
and a cut-and-sew Cox maze procedure for atrial fibrillation (permanent, 74%;
persistent, 7%; paroxysmal, 16%). Rhythm documented on 2367 postoperative
electrocardiograms was used to estimate the prevalence of atrial fibrillation across
time.
Results: Hospital mortality was 1.9%. Postoperative atrial fibrillation prevalence
peaked at 36% at 2 weeks, decreasing to 21% at 5 years. Risk factors for higher
postoperative atrial fibrillation prevalence varied with time and included longer
duration of preoperative atrial fibrillation (P  .003), larger left atrial diameter
(P  .01), older age (P  .0002), and higher left ventricular mass index (P  .02).
Conclusions: In some patients undergoing mitral valve surgery and a Cox maze
procedure, atrial fibrillation recurs over time, mandating close, long-term follow-up
of heart rhythm. Earlier operation and left atrial size reduction should be considered
to improve results in selected patients.
The Cox maze procedure, which is designed to interrupt the macroreentrantcircuits that characterize atrial fibrillation (AF) and atrial flutter,1-3 serves asthe basis for new surgical and catheter-based approaches to AF ablation.4-6
Validation of these new approaches requires comparing their results with those of
patients undergoing a cut-and-sew Cox maze procedure.7 In cardiac surgical prac-
tice AF is most frequently encountered in patients with mitral valve disease.
Although reports document the effectiveness of the Cox maze procedure in such
patients, the operation does not cure AF in all.8-12 Therefore, we sought to determine
the time-related prevalence of AF and its risk factors after combined Cox maze and
mitral valve surgery.
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Patients
From November 1991 through January 2004, 263 patients under-
went combined mitral valve surgery (repair in 71% and replace-
ment in 29%) and a Cox maze procedure (Cox maze II in 4 and
Cox maze III in 259) at The Cleveland Clinic Foundation. All Cox
maze procedures were performed with cut-and-sew and cryo-
thermy techniques, as described by Cox and associates,1 and
included an incision to the mitral annulus and cryolesions at the
mitral annulus and coronary sinus. Left atrial size reduction was
not used routinely in those with left atrial dilatation. Patients were
identified from the Cardiovascular Information Registry, and pre-
operative, operative, and postoperative variables were retrieved;
the registry has been approved for research by the institutional
review board. Mean patient age was 62  11 years, and 61% had
degenerative, 26% had rheumatic, and 3.8% had ischemic mitral
valve disease (Table 1).
AF was classified as paroxysmal (16%), persistent (7%), or
permanent (74%) according to established guidelines.13 The me-
dian duration of preoperative AF was 48 months, and 85% of
patients had AF of 1 years’ duration or greater. Mean left atrial
diameter was 5.8  1.2 cm, and left atrial diameter was greater
than 6 cm in 41%. Preoperative treatment of AF consisted of
antiarrhythmic medications in 25% and warfarin in 39%. Preop-
erative thromboembolic events included transient ischemic attack,
stroke, and other systemic embolism in 18%.
Follow-up
Postoperative electrocardiograms (ECGs) were used to assess AF.
They were performed routinely before discharge and at the discre-
tion of referring physicians during follow-up. Recommended ECG
follow-up intervals were 1 month, 3 months, 6 months, 1 year, and
annually thereafter. A total of 2367 postoperative ECGs were
retrieved, and every patient had at least one record available for
analysis (range, 1 day to 12 years). Among surviving patients, 210
(83%) had an ECG 6 months or more after the operation, and 181
(72%) had one 12 months or more after the operation (Figure 1).
For purposes of analysis, any one of the following 3 rhythms was
considered postoperative AF: AF, atrial flutter, or a paced rhythm
with underlying AF or atrial flutter.
Clinical follow-up for survival, morbid events, and medication
history was obtained by means of patient visit and systematic
telephone or mailed questionnaires. Median clinical follow-up was
2.6 years, with a total of 918 patient-years available for analysis.
Mean clinical follow-up was 3.5  2.8 years (range, 6 days to 12
years). Clinical follow-up was available in 98% of patients at 6
months and 94% at 12 months. Use of class I and class III
Abbreviations and Acronyms
AF  atrial fibrillation
CL  confidence limit
ECG electrocardiogramantiarrhythmic drugs and warfarin was recorded at each follow-up.
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Characteristic n* No. %
Atrial fibrillation 263
Duration (mo) 12, 48, 144†
Paroxysmal 41 16
Persistent 18 7
Permanent 196 74
Flutter 8 3.0
Preoperative cardioversion 22 8.4
Mitral valve disease cause 263
Degenerative 160 61
Rheumatic 67 26
Ischemic 10 3.8
Functional 15 5.7
Other 11 3.8
Demography 263
Male sex 143 54
Age (y) 62  11‡
Symptomatology
NYHA functional class 263
I 37 14
II 160 61
III 56 21
IV 10 3.8
Transient ischemic attack§ 263 32 12
CVA§ 263 23 8.7
Embolus§ 263 2 0.8
Other cardiac comorbidity
Coronary artery disease
Left main trunk disease 252 6 2.4
LAD disease 252 37 15
Circumflex disease 251 29 12
Right coronary disease 252 28 11
Previous cardiac operation 263
0 224 85
1 34 13
2 5 1.9
Cardiac structure and function
LV end-diastolic diameter (cm) 231 5.1  1.0‡
LV end-systolic diameter (cm) 229 3.5  0.91‡
LA diameter (cm) 222 5.8  1.2‡
Fractional shortening 229 0.35  0.11‡
Ejection fraction (%) 229 62  15‡
Previous myocardial infarction 263 40 15
Noncardiac comorbidity
Hematocrit (%) 231 40  5‡
Creatinine (mg · dL1) 261 0.8, 1, 1.2†
Procedure 263
Mitral valve repair 186 71
Mitral valve replacement 77 29
Tricuspid valve repair 66 25
Tricuspid valve replacement 1 0.4
Aortic valve repair 2 0.8
Aortic valve replacement 11 4.2
CABG 48 18
NYHA, New York Heart Association; CVA, cerebrovascular accident; LAD,
left anterior descending coronary artery; LV, left ventricle; LA, left atrium;
CABG, coronary artery bypass grafting. *Data available. †Median and 15th
and 85th percentiles. ‡Mean  standard deviation. §Not mutually exclusive.
50% stenosis.
ember 2005
Gillinov et al Surgery for Acquired Cardiovascular Disease
A
CDPatients were questioned concerning recurrence of symptomatic
AF and palpitations, and those with symptoms suggesting arrhyth-
mias were referred for ECG confirmation; only AF documented by
means of ECG was analyzed.
Data Analysis
Prevalence of AF and its risk factors. Because there is no
practical method for continuous heart rhythm assessment, a novel
statistical technique was developed to depict prevalence of AF
versus time on the basis of discrete ECG recordings. We attempted
to solve multiple challenges simultaneously: repeated ECG record-
ings for each patient (repeated measures), variable recording times,
censoring by death, and a complex temporal pattern of AF prev-
alence that likely represented the variable effect of different mod-
ulating factors across time. The analytic approach taken was tem-
poral decomposition with several simple additive components.14,15
Multivariable analysis was performed in the odds domain to iden-
tify risk factors for each component and overall (Electronic
Appendix).16,17
Presentation
Continuous variables are presented as means  standard deviation
or equivalently as 15th, 50th (median), and 85th percentiles when
the distribution of values was skewed. Non–time-related event data
and time-related prevalences are presented as percentages with
asymmetric 68% confidence limits (CLs) comparable with 1
standard error. The CLs for the prevalence of AF were obtained
with the bootstrap percentile method.18
Results
In-hospital Results
Hospital morbidity included stroke in 3 (1.1%) patients,
transient ischemic attack in 2 (0.8%) patients, and reopera-
Figure 1. Number of patients with electrocardiographic (ECG)
follow-up available at and beyond various time points and num-
ber of ECGs available for analysis at and beyond these same time
points.tion for bleeding in 15 (5.7%) patients. New permanent
The Journal of Thoracicpacemakers were required in 18 (6.8%) patients, and free-
dom from pacemaker implantation was 91% (CL, 89%-
93%) at 6 months. Direct-current cardioversion of periop-
erative AF was performed on 56 (21%) patients before
hospital discharge. There were 5 hospital deaths (1.9%; CL,
1.1%-3.2%).
Heart Rhythm
Prevalence of AF and its risk factors. Time-related
predicted prevalence of AF or atrial flutter after the opera-
tion peaked at 36% (CL, 31%-42%) at 2 weeks (Figure 2,A).
By 6 months, the prevalence had fallen to 13% (CL, 11%-
17%). At 3 years, it was 20% (CL, 16%-24%), and there-
after it remained relatively constant. Ten percent of patients
were taking antiarrhythmic medications 3 years postopera-
tively, and 45% were taking warfarin; these figures were
similar at 5 years.
Figure 2. Temporal pattern of atrial fibrillation (AF) after ablation
on the basis of postoperative electrocardiograms. A, Estimated
prevalence of AF. The solid line represents mean prevalence, and
dashed lines represent 68% confidence limits. B, Temporal de-
composition of prevalence demonstrating 3 additive phases: an
early peaking phase, a late phase, and a constant phase.
and Cardiovascular Surgery ● Volume 130, Number 6 1655
eter. B, Duration of preoperative AF. C, Patient age.
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components, and multivariable analysis identified different
factors modulating each (Table 2), as well as overall preva-
lence (Figure 2,B). Longer duration of preoperative AF (P 
.003) and older age (P  .0002) increased the overall
prevalence of AF, whereas larger left atrial diameter in-
creased the prevalence of AF in both the late (P  .02) and
constant time phases (P  .01, Figure 3). Five years after
the operation, the predicted prevalence of AF was only 5%
in a patient with a 4-cm left atrium; in contrast, the predicted
prevalence was 15% in a patient with a 6-cm left atrium.
The type of AF and the cause of mitral valve disease did not
affect the prevalence of postoperative AF.
Discussion
Maze Procedure in Patients With Mitral Valve Disease
In patients undergoing combined mitral valve and Cox maze
surgery, Cox and colleagues reported 98% cure of AF.3,19
Prasad and associates20 observed a greater than 90% free-
dom from AF in patients having a Cox maze procedure with
concomitant surgery. In contrast, others have used a classic
cut-and-sew technique and reported less success. Raanani
and coworkers8 recorded sinus rhythm in only 75% of
patients a mean of 26 months after Cox maze and mitral
valve surgery, which is similar to the Mayo Clinic expe-
rience of 74% freedom from AF at 2 years.9 These results
are similar to Japanese experiences with modified lesion
sets.10-12 Results from these groups are consistent with
our 18% prevalence of AF at 2 years.
TABLE 2. Incremental risk factors for higher prevalence of
atrial fibrillation
Risk factor Estimate SE P value
Overall
Longer duration of preoperative AF* 0.14 0.047 .003
Older age† 1.02 0.27 .0002
Lower creatinine‡ 0.62 0.42 .1
Early phase
Higher hematocrit§ 4.3 1.04 .0001
Constant phase
Higher LV mass index 0.38 0.16 .02
Larger LA diameter 0.35 0.14 .01
Late phase
Larger LA diameter¶ 2.6 1.1 .02
Right coronary disease# 1.2 0.36 .002
Higher hematocrit§ 3.1 0.85 .0003
SE, Standard error; AF, atrial fibrillation; LV, left ventricular; LA, left atrial.
*(Duration of preoperative AF/40), rescaled. †Exp(age/70), exponential
transformation. ‡(1/Creatinine), inverse transformation. §(Hematocrit/40)2,
squared transformation. (LV mass index/125)2, squared transformation.
¶Ln(LA diameter), logarithmic transformation. #Disease greater than 0%.1656 The Journal of Thoracic and Cardiovascular Surgery ● DecFigure 3. Prevalence at 5 years of postoperative atrial fibrillation
(AF) demonstrating effects of factors identified by multivariable
analysis (Table 2). Except for the variables depicted, values for
other risk factors were set as follows: duration of preoperative
AF, 48 months; age, 62 years; creatinine, 1.0 mg · dL1; hematocrit,
40%; left ventricular mass index, 125 g · m2; left atrial (LA)
diameter, 5.6 cm; right coronary artery stenosis, 0%. A, LA diam-ember 2005
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With Mitral Valve Disease
No patient in this study had a postoperative electrophysi-
ologic study. Without such studies to investigate the causes
of AF after a Cox maze procedure, it is impossible to
identify all the reasons for disparate results from different
groups. However, some of these failures and disparities
might be related to (1) possible variance in conduct of the
Cox maze operation, (2) patient selection, and (3) differ-
ences in follow-up methodology, data analysis, and
reporting.
Conduct of the Cox maze operation. The Cox maze III
procedure includes accurately placed surgical incisions and
cryolesions in both atria.1 Thus, results of modifications of
this procedure report data on similar, but different, opera-
tions.10 We have adhered strictly to the lesion set and
techniques of the Cox maze III procedure, including cre-
ation of lesions at the mitral annulus and coronary sinus;
alternative energy sources were not used. As noted previ-
ously, left atrial reduction was not performed.
Patient selection. As demonstrated in this and previ-
ous studies,21-24 patient characteristics influence out-
comes. Risk factors for return of AF after the Cox maze
procedure include duration of preoperative AF, left atrial
enlargement, reduced left ventricular function, and lower
f-wave voltage.21-24
Our data demonstrate that the association between left
atrial diameter and return of AF is a continuous relationship;
there is no clear cut-off value beyond which restoration of
sinus rhythm is impossible. In patients with left atrial dila-
tation, Romano and colleagues25 have demonstrated that
combining atrial reduction plasty with a Cox maze III
procedure resulted in 89% of patients being in sinus rhythm
at a mean follow-up of 19 months. During the time of our
study, we did not perform routine atrial reduction plasty in
patients with left atrial enlargement, and this might be an
important factor explaining our results.
Follow-up methodology, data analysis, and reporting.
Differences in follow-up methodology, data analysis, and
reporting render comparisons between reports problematic.
All studies of heart rhythm are limited by data collection.
Although symptomatic status related to heart rhythm is
important, there is no substitute for electrical documentation
of heart rhythm. Furthermore, asymptomatic AF is common
after ablation, even in patients who previously experienced
symptoms with AF,26-28 rendering patient-initiated event
records of questionable sensitivity and specificity. Many
reports rely on “heart rhythm at last follow-up” or patients’
self-reported rhythms without ECG verification8-10; such
methodology might underestimate the prevalence of post-
operative AF and, by focusing on a single time point, does
not enable depiction of heart rhythm over time.
The Journal of ThoracicCurrently, there are no practical means for long-term,
continuous heart rhythm monitoring. Data for analyzing
ablation success consist of ECGs, recordings from Holter
monitors, and, more recently, technology that enables either
periodic transtelephonic monitoring or continuous heart
rhythm monitoring for short periods.26-28 Each of these
provides only a snapshot in time. The more extensive the
documentation of heart rhythm, the greater the likelihood
that episodes of AF will be detected.26-29 Therefore, it is
possible that studies incorporating more closely spaced fol-
low-up data points for heart rhythm will report a greater
prevalence of postoperative AF than those relying on patient
self-reporting or on rhythm at last follow-up assessment.
A number of techniques have been used to analyze and
display heart rhythm data. Challenges related to analysis
include inability in most cases to identify the onset of AF
and data sets that include multiple assessments of heart
rhythm at varying times. Analyses that rely on the Kaplan-
Meier estimator generally use the first occurrence of AF;
this strategy ignores other episodes of AF and does not
account for the paroxysmal nature of AF in many patients.
In this study we estimated the prevalence of AF at any
given time after ablation. In such a depiction, a given patient
might have AF on one ECG and sinus rhythm on the next,
unlike in time-to-event analysis. Because prevalence in-
cludes both occurrence and duration, it might produce val-
ues that appear less favorable than those from a method that
assesses only the first occurrence of AF. We believe that
future efforts that quantify AF burden on the basis of
continuous monitoring or consistent periodic monitoring
will importantly advance the assessment of therapies de-
signed to treat AF.
Limitations
ECGs used for analysis were obtained routinely in the
hospital but opportunistically after hospital discharge. At-
tempts were made to contact each patient and cardiologist to
obtain both clinical and ECG follow-up. Two hundred ten
(83%) patients had ECGs beyond 6 months postoperatively.
Patients having late ECGs might be selected because they
had symptomatic AF, leading to overestimation of the
prevalence of AF and ablation failure. Alternatively,
asymptomatic AF episodes without ECG verification
might have been missed, leading to underestimation of
events. Although periodic Holter monitoring and periodic
transtelephonic monitoring would have provided more
data for analysis, these methodologies might still have
failed to capture all AF episodes.26-29 Our limited ability
to document heart rhythm continuously over time led us
to develop novel statistical methods that we believe pro-
vide the most accurate estimates of AF prevalence
achieved to date. Although not perfect, this method rep-
and Cardiovascular Surgery ● Volume 130, Number 6 1657
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on rhythm at last follow-up or patient self-reporting.15,30
Analyses of prevalence of AF do not account for antiar-
rhythmic medications. Prevalence of antiarrhythmic use is
reported separately (Electronic Figure). Although we rec-
ommend discontinuing antiarrhythmics 3 months after ab-
lation, continued use is at the discretion of referring cardi-
ologists, hampering our ability to report prevalence of AF
without medications.
All patients in this series received a cut-and-sew Cox
maze procedure (Cox maze III procedure in 98%), with
cryolesions at the coronary sinus, mitral annulus, and tri-
cuspid annulus. Patients in this report had left atrial enlarge-
ment and mitral valve disease. Left atrial reduction was not
used, and this might have affected results.19,20,25 These
results might not be generalizable to patients with normal
left atrial dimensions or to those without mitral valve
disease.
Clinical Inferences
Earlier operation and left atrial size reduction should be
considered in patients undergoing mitral valve surgery with
longstanding AF and left atrial enlargement, respectively.
Improved methodology for monitoring heart rhythm is nec-
essary to enable assessment of AF burden after ablation.
We thank Trish White and Jeanne Shewchik, RN, for assistance
with follow-up and Tess Parry for expert editorial assistance.
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Dr Ralph Damiano (St Louis, Mo). Dr Gillanov, I would like to
congratulate you and your colleagues at the Cleveland Clinic on a
beautiful study and for continuing to evaluate and examine your
results in the surgical treatment of atrial fibrillation (AF). It is
precisely these types of studies that are sorely needed to help us
define on whom, when, and how we should perform these opera-
tions.
Your study reported predictors of failure in 263 patients who
underwent mitral valve surgery and a concomitant Cox maze
procedure between 1991 and 2004. The principal risk factors for
late return of AF included longer duration of preoperative AF,
larger left atrial volume, and lower ejection fraction. This agrees
with our experience, which we presented last year here at the
American Association for Thoracic Surgery, with 278 consecutive
patients undergoing the Cox maze procedure in whom we found
preoperative duration of AF and the type of Cox maze procedure
to be the most important predictors of late recurrence. I have
several questions.
First, your median follow-up in this series was 2.6 years. How
many of these patients in the study were lost to follow-up? More
particularly, because you required electrocardiographic (ECG) ev-
idence to confirm AF, how many patients did not have ECG
follow-up at each time point? You reported in the article that only
72% of patients had ECGs at 1 year. Thus, we can assume that
28% were lost at a year. How about at 2 and 5 years, and could
these patients who were lost to follow-up have influenced your
findings?
What if the patient reported that he or she had AF, but you were
unable to obtain ECG documentation of the arrhythmia? If you had
included these patients as failures, how would this have influenced
your rate of late recurrence?
My third question involves the antiarrhythmic drug use during
the follow-up period. As you stated in your introduction, this is a
critical piece of information that we as surgeons must begin to
report in our series. Because a number of these patients might not
have ever been tried on antiarrhythmic drugs preoperatively, their
maintenance of sinus rhythm postoperatively might be due to more
aggressive antiarrhythmic drug management after the operation.
We would both agree that high success rates without antiarrhyth-
mic drugs should be our ultimate goal as surgeons in this area.
Finally, my last question is regarding left atrial size. You
mentioned that it is an important determination of failure and
recurrence of AF. I was wondering whether you could elucidate on
what you believe the role of atrial reduction is in these patients. In
particular, at what size would you recommend an atrial reduction
procedure? Also in this series, how many of the patients actually
had atrial reduction procedures? Dr McCarthy, when he was at
your institution, was quite a proponent of this procedure.
Once again, I would like to congratulate you on your very nice
work, and I would like to thank the Association for allowing me to
comment on this very important article. Thank you.
Dr Gillinov. Thank you for your comments, Ralph. Your first
question gets to a key point that we are studying very intensely.
How do you assess heart rhythm, and how do you follow these
patients? We are subject to the same limitations as all others. We
do not have continuous monitoring of heart rhythm. What did we
have? At 6 months, we had clinical follow-up on 98% of patients
The Journal of Thoracicand ECG follow-up on 83%. At 12 months, we had clinical
follow-up on 94% and ECG follow-up on 72%. Therefore, with
time, more patients were certainly lost to follow-up.
I cannot tell you exactly how many had follow-up at 3 years or
5 years, although I can tell you that at 5 years we still had 40
patients with more than 5 or 6 ECGs per patient at that point and
thereafter. With the new methodology devised by Dr Blackstone
and his team, this provides sufficient data for analysis.
What do we do with the patient who says, “I think I am in AF
but I don’t have an ECG”? It is not that we do not believe the
patient, but we do not count that as data. We advise the patient to
get an ECG because what we want is electrical documentation of
the heart rhythm. In truth, though, that was an uncommon occur-
rence.
Antiarrhythmic drug use certainly must influence results. It
makes sense that if we have people taking antiarrhythmic drugs,
our results might be influenced by them. At 3 years, 10% of the
patients were taking antiarrhythmic medications, and it remained
constant thereafter. Therefore, the majority were not taking anti-
arrhythmic agents.
Finally, what about left atrial size? We and many others have
found that increasing left atrial size is associated with a decrease in
succession. Some have suggested that there is a particular cutoff,
5 cm or 6 cm, beyond which you should consider doing something
about the left atrial size. In fact, like most things in nature, it is a
continuous relationship. That being said, I will tell you what we do
now.
If the atrium is 6 cm or greater, as measured by echocardiog-
raphy, in any dimension, we will cut out a portion. In this partic-
ular series, very few patients had left atrial size reduction. We
became more aggressive with a strategy of size reduction only in
the last year or two.
Dr Niv Ad (Falls Church, Va). I enjoyed very much your
presentation. With regard to left atrial size and left atrial reduction,
I wonder what your comment is as for a possible explanation of
high success rate early on, even with very big left atrial size and
then a failure that occurs late in the follow-up. Assuming that you
have transmural lesions and that there is no question about it,
because in this series the cut-and-sew maze procedure was per-
formed, then the only explanation for late failures that make sense
is the sick atrial substrate. Atrial remodeling can be severe in some
patients and a major factor for failure down the road, and I am
personally not convinced that you can take care of this by just
reducing the size of the atrium. Because you have an initial high
success rate, why would they fail if you fix the mitral valve and
you do not have any AF? Therefore, do you think that the atrial
substrate and irreversible changes could be responsible for late
failures in some patients?
Dr Gillinov. Actually, I can give you an answer that has some
preliminary data to back it up.
All of these patients had their left atrial appendages removed,
and for more than a decade, we have been examining these left
atrial appendages. What we find is that in patients with very
long-term AF, which correlates with large left atria, they tend to
have a large left atrium and permanent AF of long duration, and
their atria have intense inflammatory reactions, scar, and fibrosis.
And I think you are right. What that patient brings to the operating
room might make it such that we can never restore, at least
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correctly.
Dr Ad. Maybe we should not modify the antiarrhythmic drug
treatment postoperatively in such patients, keeping them on longer
treatment regimens and discontinuing therapy only under very
tight follow-up and monitoring.
I am convinced that some patients should be kept on anti-
arrhythmic drugs for life, because their atrial substrate and the
changes are irreversible and their atrium is prone to recurrent
atrial arrhythmia. Therefore, it is not the left atrial size as a
predictor for failure. It is the atrial size as a marker for the
severity of the disease, and it is all about the substrate and
reverse remodeling.
Dr Gillinov. I am not sure you can separate those. They go
together. But you might very well be right. A strategy of long-term
antiarrhythmic therapy might improve our results in those patients.
Dr D. Craig Miller (Stanford, Calif). Mark, that was a splendid
presentation. I congratulate you. But you admit freely and honestly
that you do not have a complete radar system to follow these patients
forever; you do have more complete clinical follow-up than ECG
follow-up. Do you have the data on how many patients, wrongly or
rightly, were still receiving warfarin anticoagulation at the various
points in time? This statistic might serve as a practical surrogate for
what the local physicians think is going on?
Dr Gillinov. We have those data, but I am not sure what to do
with them. Forty-five percent of patients were still receiving war-
farin at 3 years, and over the next several years, it was relatively
constant. Now, about a quarter of those people had a mechanical
valve, a few have had a deep venous thrombosis, and many of
them have had no documented AF because we have contacted
them, but each time they see their physician, AF comes up on their
list of diagnoses, and that leads straight to warfarin. Unfortunately,
we do not have control of those patients. It is possible that it is
right to keep all of them on warfarin. I am not sure.
Dr Miller. Good point. My last question is to look into your
crystal ball and tell us what you would speculate those freedom-
from-AF curves would look like had you not done an adjunctive
Cox maze procedure, such as in a legitimate control group that we
all need.
Dr Gillinov. In these patients I think that 80% or more would
have stayed in AF because 74% came to us with permanent AF,
and 85% had AF for more than a year preoperatively. There are
some data that suggest the possibility that in certain patients with
new-onset AF, just fixing the mitral valves makes the AF go away.
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the AF will disappear with mitral surgery alone.
Dr Takashi Nitta (Tokyo, Japan). Congratulations on the
excellent presentation and data analyses. Early recurrence of AF
might be the result of electrical remodeling caused by long-lasting
AF preoperatively. This subset of patients might be treated with
amiodarone, and sinus rhythm would resume when the refractory
period returns to the normal range. However, the mechanism for
the AF recurrence occurring midterm or late term after the oper-
ation remains unclear.
In my series the postoperative AF recurrence rate was about
11% among the patients with permanent AF and mitral valve
disease. Our EP fellows are doing an EP study on the patients in
whom AF recurs more than 1 month after surgical intervention.
Interestingly, they found residual conduction over the coronary
sinus, which is a technical failure, as the cause of recurrence of AF
in about two thirds of the patients. They also found rapid activation
from nonpulmonary vein foci as the cause of AF.
I have 2 questions for you. Did you see any correlation between
the phase of AF recurrence and the other risk factors, such as left
atrial diameter, older age, or longer duration of preoperative AF?
Second, would you speculate the mechanism of AF recurrence
in each phase?
Once again, congratulations on the excellent article.
Dr Gillinov. Thank you. What he is getting at is that the
recurrence of AF occurs at different time frames. It can occur
early, late, or during a constant phase of risk, and each of these
clinical risk factors, like left atrial diameter, has an effect at a
different time frame.
For example, older age might be more important with the
constant phase, whereas it turns out, for reasons that are not
entirely clear, that a higher hematocrit level is associated with
early recurrence of AF. Therefore, yes, there are a variety of
relationships that require further study.
As for speculating on the mechanisms of failure, actually you
have the data, and we do not. Your mapping studies are going to
pave the way. But I suspect it is a combination of one of 2 factors.
Either we have done the procedure incompletely—for example,
left a pathway near the coronary sinus as you and Dr Cox have
noted—or the patient has a substrate that perhaps cannot be cured
with a standard maze procedure, maybe atrial scar, fibrosis, in-
flammation. I think that, as with any therapy, there will be some
patients who will not be amenable to it.
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Patient
Atrial fibrillation types: Permanent, persistent, paroxysma
Mitral valve disease: Cause (degenerative, rheumatic,
Demography: Age (years), sex, weight (kg), hei
Symptoms: New York Heart Association func
cerebrovascular accident
Other cardiac comorbidity: Complete heart block/pacer, vent
Other valve pathology: Aortic valv
Coronary artery disease: Maximu
coronary artery system, right c
Left ventricular function: Ejection
fractional shortening, mass (g),
volume (mL), end-diastolic volu
wall thickness (cm), estimated
Right ventricular function: Estima
Atrial size: Left atrial (LA) diamete
Noncardiac comorbidity: Insulin-treated diabetes, non–insu
disease, history of smoking, ca
renal disease, creatinine (mg ·
hematocrit (%)
Procedure
Operation: Internal thoracic artery grafting, c
(MV) repair, MV replacement, M
Support: Aortic clamp time (minutes), card
Experience: Date of operation (years since JaA
CDl, duration (months)
ischemic, degenerative), pathophysiology (regurgitation)
ght (cm), body surface area (m2), body mass index (kg · m2)
tional class (I-IV), emergency operation, transient ischemic attack,
ricular arrhythmia, number of previous cardiac operations
e regurgitation, tricuspid valve regurgitation
m percentage stenosis in left main trunk, left anterior descending
oronary artery system, left circumflex coronary artery system
fraction (%), end-diastolic diameter (cm), end-systolic diameter (cm),
mass index (g · m2), end-diastolic volume (mL), end-systolic
me index (mL · m2), end-systolic volume index (mL · m2), posterior
wall stress (2  posterior wall thickness/end-diastolic diameter)
ted systolic pressure
r (cm), LA volume (mL), LA volume index (mL · m2)
lin-treated diabetes, treated diabetes, history of peripheral vascular
rotid disease, chronic obstructive pulmonary disease, hypertension,
dL1), blood urea nitrogen (mg · dL1), bilirubin (mg · dL1),
oronary artery bypass grafting, tricuspid valve repair, mitral valve
V bioprosthetic replacement, aortic valve replacement
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CDElectronic Figure. Prevalence of class I/III antiarrhythmic agent
and warfarin use after ablation. Horizontal axis begins at 3
months, marking the first systematic follow-up of patients. Filled
circles are observed prevalences but only approximate the data
because of multiple follow-up inquiries per patient. The solid line
represents the prevalence estimate from logistic mixed model
enclosed within dashed 68% confidence limits. A, Prevalence of
class I/III antiarrhythmic agent use. B, Prevalence of warfarin
use.1660.e2 The Journal of Thoracic and Cardiovascular Surgery ● December 2005
